{"nct_id":"NCT01083615","title":"A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)","status":"TERMINATED","status_verified_date":"2016-10","start_date":"2010-03","start_date_type":null,"primary_completion_date":"2013-03","primary_completion_date_type":"ACTUAL","completion_date":"2013-03","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["ACHV"]}